Ixabepilone
As of the edition of 20 October 2026, Ixabepilone is a small molecule: marketed, first approved in 2007 (US); acts on TUBB, TUBB1 and TUBB2A and 6 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Small molecule
- Brand name
- Ixempra Kit
- First approved
- 16 October 2007 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- R-Pharm
- Registered trials
- 109, 24 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 1 |
| Phase 1 | 31 | 22 | 1 | 6 |
| Phase 2 | 69 | 52 | 2 | 15 |
| Phase 3 | 7 | 5 | 0 | 2 |
| All trials | 109 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| R-Pharm | Acquired holder and Lead sponsor of trials | 1999 to now |
| Bristol Myers Squibb | Earlier holder and Lead sponsor of trials | 2001 to now |